Australian-based pharmaceutical developer Firebrick Pharma debuted on the ASX today with a bang, skyrocketing more than 200% during its debut session.
Firebrick Pharma is focused on its patented Nasodine nasal spray to treat viruses including the common cold.
The company has a number of clinical trials planned later in the year.